Petri M
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rheum Dis Clin North Am. 1998 May;24(2):423-56. doi: 10.1016/s0889-857x(05)70016-8.
The improved survival of SLE patients since the 1950s is the result of not only better treatment, but also supportive treatment of renal failure and the wealth of antibiotics now available. Ironically, the wider use of immunosuppressives, especially the alkylating drugs, and the longer survival of patients with renal insufficiency and renal failure have made the identification and appropriate treatment of infection in SLE an ongoing challenge.
自20世纪50年代以来,系统性红斑狼疮(SLE)患者生存率的提高不仅得益于更好的治疗,还得益于对肾衰竭的支持性治疗以及现有种类丰富的抗生素。具有讽刺意味的是,免疫抑制剂尤其是烷化剂的广泛使用,以及肾功能不全和肾衰竭患者生存期的延长,使得识别SLE患者的感染并进行恰当治疗成为一项持续的挑战。